www.fdanews.com/articles/85619-optimer-initiates-clinical-trials-of-opt-99-for-gastroenteritis
OPTIMER INITIATES CLINICAL TRIALS OF OPT-99 FOR GASTROENTERITIS
March 28, 2006
Phase III
clinical trials of Optimer's OPT-99 for bacterial gastroenteritis are scheduled
to begin in May 2006, the company has announced. The company plans to develop
OPT-99 for the treatment of bacterial gastroenteritis including traveler's diarrhea.
Optimer will conduct two independent, international Phase III trials.
Investigators will begin to enroll patients in mid-May 2006 in the U.S., Mexico,
and Peru; the second trial will soon follow in India and Africa.